key: cord-0712864-obay4ibk
authors: Dakay, Katarina; Cooper, Jared; Bloomfield, Jessica; Overby, Philip; Mayer, Stephan A.; Nuoman, Rolla; Sahni, Ramandeep; Gulko, Edwin; Kaur, Gurmeen; Santarelli, Justin; Gandhi, Chirag D.; Al-Mufti, Fawaz
title: Cerebral Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The Literature
date: 2020-11-06
journal: J Stroke Cerebrovasc Dis
DOI: 10.1016/j.jstrokecerebrovasdis.2020.105434
sha: 02d8b10b88b1b50c216ff85cba57950130f4cd29
doc_id: 712864
cord_uid: obay4ibk

SARS-CoV-2, the virus responsible for novel Coronavirus (COVID-19) infection, has recently been associated with a myriad of hematologic derangements; in particular, an unusually high incidence of venous thromboembolism has been reported in patients with COVID-19 infection. It is postulated that either the cytokine storm induced by the viral infection or endothelial damage caused by viral binding to the ACE-2 receptor may activate a cascade leading to a hypercoaguable state. Although pulmonary embolism and deep venous thrombosis have been well described in patients with COVID-19 infection, there is a paucity of literature on cerebral venous sinus thrombosis (cVST) associated with COVID-19 infection. cVST is an uncommon etiology of stroke and has a higher occurrence in women and young people. We report a series of three patients at our institution with confirmed COVID-19 infection and venous sinus thrombosis, two of whom were male and one female. These cases fall outside the typical demographic of patients with cVST, potentially attributable to COVID-19 induced hypercoaguability. This illustrates the importance of maintaining a high index of suspicion for cVST in patients with COVID-19 infection, particularly those with unexplained cerebral hemorrhage, or infarcts with an atypical pattern for arterial occlusive disease.

Hematologic effects of SARS-CoV-2 infection have been increasingly recognized and documented in recent literature. An atypically high incidence of venous thromboembolism (VTE) has been reported ranging from 7.7 to 28.0% in patients hospitalized with COVID-19 associated pneumonia even with appropriate VTE prophylaxis. 1, 2 Previous studies have demonstrated that COVID-19 infection is associated with an increase in prothrombotic markers such as fibrinogen and D-dimer, as well as inflammatory markers such as C-reactive protein and interleukin-6, 3 which are associated with a hypercoaguable state. Similarly, ischemic stroke, in particular, cryptogenic stroke, has been reported in patients with COVID-19. 4 More recently, cases of cerebral venous sinus thrombosis have been reported in patients with COVID-19 infection. 5À8 Cerebral venous sinus thrombosis (cVST) is an uncommon subtype of stroke with an annual incidence of 2À5 cases per million people. Unique to this subtype of stroke is a predilection for younger patients, particularly women. Headache is the most common presenting symptom, followed by seizures, then focal neurologic deficits. 9 In many cases, a risk factor such as an inherited coagulopathy, an antecedent history of trauma, cancer, or hormonal contraception can be identified. Recently, SARS-CoV-2 has been postulated as a risk factor for cVST by inducing a hypercoaguable state. Interestingly, although data is limited, there appears to be a roughly equal incidence in males and females with COVID-19-associated cVST. We report on three cases of cVST associated with COVID-19 admitted to our hospital, as well as a review the other cases reported in recent literature.

We report on three separate cases of dural venous sinus thrombosis occurring in patients with SARS-CoV-2 infection at our institution.

A 17 year old boy with a history of obesity who had tested positive for SARS-COV-2 two weeks prior to admission presented with two weeks of new-onset leftsided headaches, worst upon awakening in the morning, and with occasional emesis. He had been diagnosed with COVID-19 infection on a prior medical visit for new-onset hypertension and headaches, and had not endorsed cough or any respiratory symptoms. Additionally, he noted blurred vision. On admission, he was alert and oriented with no focal neurologic deficits on exam. Blood pressure on presentation was 138/88 mmHg. Fundoscopic exam revealed papilledema. MRI brain with MR venography revealed extensive dural venous sinus thrombosis involving the straight sinus, torcula, left transverse and sigmoid sinus, extending into the jugular vein, as well as right transverse sinus, superior sagittal sinus and left vein of Labbe (Fig. 1) . He had no family history of thrombotic disease and did not take any prothrombotic medications. He was started on therapeutic anticoagulation with enoxaparin and admitted to the pediatric intensive care unit. Admission labs were significant for elevated D-dimer of 1.13 and otherwise normal coagulation parameters (see Table 1 ). A thorough hypercoaguability workup including homocysteine, anticardiolipin antibodies, antithrombin III, protein C, protein S, prothrombin gene mutation, Factor V Leiden genetic mutation, and beta-2-glycoprotein were unremarkable. As anticipated with an acute thrombotic event, Lipoprotein A was markedly elevated at 125.40 nmol/L, and Factor VIII activity was elevated at 261%. His neurologic status remained stable throughout his hospital course. He was discharged home on anticoagulation on hospital day 10. He presented again to the hospital two weeks later, with transient visual disturbances, which were attributed to persistent elevation in intracranial pressure. Repeat neuroimaging revealed improving clot burden. He was managed conservatively with observation and discharged shortly thereafter.

A 72 year old woman with a remote history of breast cancer in remission and not on hormonal therapy (Fig. 2) . We hypothesized that venous infarction was likely responsible for the patient's symptoms. Due to the patient's precipitously worsening condition, the family wished to transition her to comfort measures and ultimately died on hospital day six.

A 26 year old man with no past medical history other than recent SARS-CoV-2 infection was playing basketball with friends when he developed sudden-onset left sided hemiparesis followed by severe headache, nausea, and dizziness. A CT scan demonstrated a right parasagittal intracerebral hemorrhage. On admission, blood pressure was normotensive and other vital signs were unremarkable. SARS-CoV-2 rt-PCR collected on admission was positive. A few weeks prior, he had developed a mild viral syndrome and was diagnosed with COVID-19 infection, of which the symptoms had resolved. Coagulation parameters and platelet count were unremarkable. Exam was notable for left-sided hemiparesis (4/5 motor strength) with hemisensory loss. CT angiogram demonstrated prominent vessels in the right hemisphere suspicious for an arteriovenous malformation. MR venogram did not show any dural venous thrombosis, and MRI did not demonstrate a clear cortical vein thrombosis. A diagnostic cerebral angiogram was performed the next morning, which showed a developmental venous anomaly. Additionally, there was a filling defect of the right junction of the vein of Trolard with the superior sagittal sinus (Fig. 3) . We suspected that venous hypertension was likely the underlying etiology of the hemorrhage. Given the ambiguity of the findings and the presence of a sizable hemorrhage, anticoagulation was deferred and he was discharged with short-interval follow-up imaging. The patient's neurologic exam remained stable to improving at time of discharge, with some residual left-sided weakness. Subsequent repeat angiogram performed several weeks after discharge supported the diagnosis of cortical vein thrombosis, demonstrating a persistent filling defect with substantial improvement in venous drainage, and did not demonstrate any evidence of arteriovenous fistula or malformation.

These cases of COVID-19 associated cVST add to the current and growing body of literature on cVST as a potential thromboembolic complication of COVID-19. Of note, in one of our cases and in several of the reported cases in the literature, the COVID-19 infection preceded the symptoms of venous sinus thrombosis by up to two weeks. This suggests that the hypercoaguable effect of COVID-19 infection may possibly persist relative to the initial infectious event. There are many mechanisms by which SARS-CoV-2 has been postulated to enhance coagulation. First, it is known that D-dimer, fibrinogen, and fibrin degradation products are elevated relative to healthy controls. Additionally, the SARS-CoV-2 interaction with the ACE receptor may result in endothelial injury thereby promoting a hypercoagulable state. 10 A report of pulmonary embolism associated with COVID-19 appears to support this notion; as the authors suggest that cytokine storm, most prominent in the second week after symptom onset, may be associated with the hightened risk of VTE associated with the SARS-CoV-2 infection. 11 Cerebral venous thrombosis has been reported to occur in the presence of other thrombotic phenomena. For example, one report described a woman with a pulmonary embolism and superior vena cava occlusion in conjunction with dural venous sinus thrombosis. 5 In other cases, isolated cerebral venous sinus thrombosis occurred in the presence of moderate or severe COVID-19 infection 6 ; however, in our series, two patients experienced a relatively mild viral illness, suggesting that patients without severe respiratory or systemic symptoms may still suffer from comorbidities associated with viral hypercoaguability. It is possible in some of these patients that there may be a predisposing risk factor for venous sinus thrombosis, such as one reported case in which severe iron deficiency anemia was discovered in a young woman with COVID-19 and venous sinus thrombosis. 12 Additionally, as headache can be a common symptom of viral illnesses including COVID-19, diagnosis can often be elusive or delayed until symptoms worsen. 7 This effect may be compounded by the observation that COVID-19 associated cVST, in comparison to cVST of other etiologies, has less of a female predominance and can occur in patients with relatively mild or asymptomatic COVID-19. For this reason, patient's viral illness sometimes goes unacknowledged, and their COVID-19 status may not be established until presenting with symptoms related to COVID-associated neurologic conditions. 12, 8 Conclusion SARS-CoV-2 infection has been associated with a hypercoaguable state, characterized by elevated D-dimer and fibrinogen levels, and a high incidence of venous thromboembolism including pulmonary embolism and deep venous thrombosis. While venous sinus thrombosis is an uncommon etiology of stroke, our series as well as recent reports suggest that there may be an association between SARS-CoV-2 infection and the development of cerebral venous sinus thrombosis. Given that symptoms such as headache may be insidious and nonspecific, it is imperative for clinicians to consider venography in patients with COVID-19 infection who present with atypical infarct or hemorrhage patterns or unexplained elevations in intracranial pressure.

None.

Routine venous thromboembolism prophylaxis may be inadequate in the

A) Noncontrast CT brain demonstrates the right parasagittal hemorrhage; (B) diagnostic cerebral angiography, right internal carotid injection, coronal view, venous phase showing filling defect in the right junction of Trolard with superior sagittal sinus (black arrow). hypercoagulable state of severe coronavirus disease 2019

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

SARS2-CoV-2 and stroke in a new york healthcare system

Venous cerebral thrombosis in COVID-19 patient

cerebral venous thrombosis associated with COVID-19 infection: causality or coincidence?

Cerebral venous sinus thrombosis as a presentation of COVID-19

First case of COVID-19 presented with cerebral venous thrombosis: a rare and dreaded case

Cerebral venous sinus thrombosis

The need to manage the risk of thromboembolism in COVID-19 patients

Pulmonary embolism and increased levels of ddimer in patients with coronavirus disease

Cerebral venous thrombosis: atypical presentation of COVID-19 in the young